CVS Health announced that it has launched Cordavis, a wholly owned subsidiary that will work directly with manufacturers to commercialize and/or co-produce biosimilar products for the U.S. pharmaceutical market. The Cordavis products will be FDA approved, high quality, and easy for patients to use and will help ensure consistent long-term supply of affordable biosimilars. As its first product, Cordavis has contracted with Sandoz to commercialize and bring to market Hyrimoz, a biosimilar for Humira, in the first quarter of 2024 under a Cordavis private label. The list price of the Cordavis Hyrimoz will be more than 80% lower than the current list price of Humira.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CVS:
- CVS Unveils Cordavis to Offer Biosimilars. Should AbbVie (NYSE:ABBV) Worry?
- Hawaiian Electric upgraded, CVS downgraded: Wall Street’s top analyst calls
- CVS Health downgraded on PBM uncertainty at Edward Jones
- Cigna (NYSE:CI) and Others Face Aftermath of Blue Shield’s Move
- CVS Health downgraded to Hold from Buy at Edward Jones